WAKEFIELD, MA, Aug. 12 /CNW/ - NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced its financial results for the second quarter ended June 30, 2008. NUCRYST also announced today (see separate press release) that its Board of Directors has authorized a program for the Company to repurchase up to 900,000 shares of its outstanding common stock.
